About
Statin therapy is the first-line pharmacologic treatment for lowering low-density lipoprotein cholesterol (LDL-C) and reducing atherosclerotic cardiovascular disease (ASCVD) risk. However, evidence-based and guideline-recommended therapies continue to be underutilized — even among the highest risk patients. More education is needed to address gaps in ASCVD care, particularly among patients who cannot reach their LDL-C goals with statin therapy alone. NATF is pleased to launch Cholesterol Conversations, a limited-series podcast discussing the latest guidance on ASCVD management and available treatment options for optimal LDL-C lowering. New data on the efficacy of novel agents and combination therapy is also highlighted.
Podder Search